Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HP1β CRISPR/Cas9 KO Plasmid (h): sc-403235
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HP1β CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HP1β genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HP1β Antibody (4D7B8): sc-517288
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HP1β CRISPR/Cas9 KO Plasmid (h) | sc-403235 | 20 µg | $397.00 |
Overview
CBX1 encodes heterochromatin protein 1 beta (HP1β), a conserved chromatin adaptor that recognizes H3K9me2/3 via its chromodomain and helps compact chromatin through interactions with SUV39H histone methyltransferases and other repressors. HP1β contributes to heterochromatin formation, transcriptional silencing, DNA replication timing, and maintenance of genome stability by coordinating higher-order chromatin architecture. It also participates in DNA damage responses and repair pathway choice by modulating accessibility at damaged loci and influencing recruitment of repair factors. Dysregulation of HP1β-linked epigenetic programs has been associated with altered differentiation states and genomic instability observed across diverse cancer and neurodevelopmental research contexts.
HP1β CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CBX1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CBX1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CBX1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HP1β protein expression.
This CRISPR knockout system enables efficient generation of CBX1-deficient cell models for investigation of HP1β signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CBX1 exon(s) critical for HP1β function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CBX1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HP1β CRISPR/Cas9 KO Plasmid (h) and HP1β CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CBX1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HP1β HDR Plasmid (h) and HP1β HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CBX1 homology arms to support homology-directed repair at defined CBX1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.